 Valneva SE NASDAQ: VALN has commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K. Topline results from the trial, dubbed Cov-Compare, are expected early in Q4 of 2021 and are intended to form the basis for potential regulatory approval in adults. 